{"id":5701,"date":"2025-04-24T07:00:29","date_gmt":"2025-04-24T07:00:29","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solution&p=5701"},"modified":"2025-11-24T09:05:41","modified_gmt":"2025-11-24T09:05:41","slug":"nordic-pro-c3","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/nordic-pro-c3\/","title":{"rendered":"NordicPRO-C3\u2122"},"content":{"rendered":"
\n
\n
\n

The Home of PRO-C3<\/h1>\n

NordicPRO\u2011C3\u2122 is a highly reliable and precise biomarker assay that measures active fibrosis by detecting the formation of type III collagen – a key driver of fibrogenesis across major organs, including the liver, lungs, kidneys, heart, intestines, and skin.<\/p>\n

\n \n Order now \n \n <\/svg>\n \n <\/a>\n \n NordicPRO-C3\u2122: Kit in a Box \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n <\/div>\n<\/section>\n\n\n\n\n\n
\n
\n
\n

A pharmacodynamic biomarker that measures active fibrosis<\/h2>\n

As an efficacy and pharmacodynamic biomarker<\/span>,\u00a0NordicPRO\u2011C3\u2122<\/a>\u00a0(PRO-C3)\u00a0is widely used in clinical trials to monitor treatment response, demonstrate target engagement and confirm mechanism of action. In addition, its dynamic nature makes it ideal for tracking changes in fibrosis over time.<\/span><\/p>\n

As a prognostic biomarker, nordicPRO-C3\u2122 supports patient selection by identifying individuals more likely to experience disease progression or clinical outcomes \u2014 helping enrich trial populations, boost statistical power, and increase the likelihood of success.<\/span><\/p>\n

NordicPRO C3\u2122 has demonstrated value in liver diseases<\/span>\u00a0such as\u00a0metabolic-associated fatty liver disease (MAFLD)<\/a>, and\u00a0alcohol-related liver fibrosis<\/a>, while also predicting disease progression and clinical outcomes.<\/p>\n

Beyond liver disease, nordicPRO-C3\u2122 is widely used in research on lung fibrosis, tumor fibrosis (FDA-supported)<\/a>, and other conditions where fibrosis plays a central role.<\/p>\n

NordicPRO-C3\u2122\u00a0provides a powerful tool for monitoring treatment efficacy and tracking disease progression over time. Furthermore, it serves as a critical decision-making tool in clinical trials, helping researchers assess treatment impact, understand the mechanism of action, and accelerate drug development.<\/p>\n <\/div>\n

\n
\"\"<\/a><\/p>\n

Figure 1.<\/strong> NordicPRO\u2011C3\u2122 is a pharmacodynamic biomarker of active fibrosis<\/em><\/p>\n<\/div>\n <\/div> \n <\/div>\n<\/section>\n\n\n

\n \n
\n
\n
\n
\n

Why measure PRO-C3 at Nordic Bioscience?<\/h2>\n \n\n <\/div>\n
\n

At Nordic Bioscience, our approach to measurement is rooted in decades of innovation and a deep understanding of fibrosis. As the originators of PRO\u2011C3, we perfected the biomarker over 15+ years of clinical trials, built on more than 30 years of expertise in extracellular matrix biomarkers.<\/p>\n

Today, PRO-C3\/nordicPRO\u2011C3\u2122 is a household name known to ensure you receive data that is both precise and actionable.\u00a0PRO-C3 is available in three versions, each with distinct applications:<\/strong><\/p>\n

    \n
  1. \n

    Elecsys PRO-C3\u00ae (automated) \u2013 An IVD-labelled assay, in collaboration with Roche Diagnostics.<\/a><\/p>\n<\/li>\n

  2. \n

    NordicPRO-C3\u2122 \u2013 Our standard research use only (RUO) assay, measured in our CAP\/CLIA-certified lab as an exploratory endpoint or pharmacodynamic biomarker in phase I through phase IV clinical trials. It is available as part of our biomarker testing services and not for diagnostic use.<\/p>\n<\/li>\n

  3. \n

    NordicPRO-C3\u2122 (manual ELISA kit) \u2013 New! The kit can now be directly ordered from us<\/a>. The kit is FOR RESEARCH USE ONLY (RUO) and can only be used in NON-CLINICAL settings. It can not be used IN DIAGNOSTIC PROCEDURES. To learn more or order, click here.<\/a><\/p>\n<\/li>\n<\/ol>\n <\/div>\n

    \n

    Order PRO-C3<\/h3>\n